Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 9/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492709 | 0.96 | HPGDS (0.58) | HPGDSGABRA5MAPK8MAPK14 | |
| SCHEMBL4490900 | 0.96 | HPGDS (0.58) | HPGDSGABRA5MAPK8MAPK14 | |
| SCHEMBL4507738 | 0.87 | GABRA5 (0.54) | HPGDSGABRA5 | |
| SCHEMBL4510145 | 0.87 | MAPK14 (0.51) | HPGDSGABRA5MAPK8MAPK14 | |
| SCHEMBL4509398 | 0.86 | ALDH1A1 (0.50) | MAPK8MAPK14 | |
| SCHEMBL4490907 | 0.84 | MAPK14 (0.45) | HPGDSGABRA5MAPK14 | |
| SCHEMBL4504173 | 0.84 | GABRA5 (0.48) | HPGDSGABRA5MAPK8MAPK14 | |
| SCHEMBL4500969 | 0.84 | GABRA5 (0.48) | HPGDSGABRA5MAPK8MAPK14 | |
| SCHEMBL4495802 | 0.83 | ALDH1A1 (0.58) | GABRA5MAPK14 | |
| SCHEMBL4488743 | 0.82 | HPGDS (0.43) | HPGDSGABRA5MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585874-B2 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-08 | — | — | US | claimed |
| EP-1979350-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | claimed |
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | claimed |
| WO-2007082806-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | claimed |
| US-7585874-B2 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1979350-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| WO-2007082806-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | GABRA5, GABRA4, GABRA1 | HPGDS 3874/4885GABRA5 1/4885MAPK8 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.